Intellia Q4 Revenue $23.017M, Beats Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy NTLA?
Reports Q4 revenue $23.017M, consensus $12.17M. "2025 was a time of accomplishment and resiliency for Intellia as we presented encouraging longer term Phase 1/2 clinical data for both lonvo-z and nex-z, rapidly enrolled patients in our three Phase 3 trials, commenced activities to prepare for a potential lonvo-z launch in HAE and responded to the clinical holds on our nex-z Phase 3 trials late in the year," said Intellia President and Chief Executive Officer John Leonard, M.D. "We expect the year ahead to be a pivotal one, highlighted by our topline Phase 3 data and planned BLA submission for lonvo-z, which has the potential to transform the HAE treatment paradigm by freeing most patients from both their attacks and chronic therapy. Additionally, we are focused on resuming our forward momentum with nex-z by completing patient enrollment in MAGNITUDE-2 and resolving the clinical hold on MAGNITUDE."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 15.440
Low
4.00
Averages
16.50
High
54.00
Current: 15.440
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Presents New Research at AAAAI Meeting
- Clinical Trial Results: In a pooled Phase 1/2 analysis involving 32 hereditary angioedema (HAE) patients, a single 50 mg dose of lonvo-z resulted in a mean monthly attack rate of ≤0.2, representing a 96% reduction from baseline, highlighting the potential long-term safety and efficacy of lonvo-z.
- Evolving Treatment Goals: Among 28 patients who received lonvo-z, 86% achieved attack-free and long-term prophylaxis-free status after more than six months of follow-up, indicating a strong alignment between patient needs for reduced treatment burden and clinical objectives.
- Biological Modeling Study: Research indicates that significant C1-esterase inhibitor deficiency in HAE patients leads to excessive plasma kallikrein generation, with models showing that an 85% reduction in prekallikrein can normalize kallikrein and bradykinin levels, supporting the clinical efficacy of lonvo-z.
- Patient Challenge Survey: A survey of 100 HAE patients revealed that 34% experienced at least one attack per month, with only 20% being attack-free in the past year, underscoring the demand for lonvo-z as patients seek to eliminate chronic medication use to improve treatment outcomes.
See More
INTELLIA THERAPEUTICS STOCK RISES 2% FOLLOWING US FDA'S LIFTING OF CLINICAL HOLD ON HEART DISEASE GENE THERAPY TRIAL
- Stock Performance: Intelia Therapeutics shares increased by 2% following a positive development in their clinical trial results.
- Clinical Trial Focus: The trial is centered on gene therapy for treating heart disease, specifically targeting a gene associated with the condition.
See More
Cathie Wood Continues to Add to Growth Stock Positions
- MercadoLibre Financial Analysis: MercadoLibre reported a 45% year-over-year increase in net revenue and financial income to $8.8 billion in Q4, yet its operating profit rose only 8% due to a 50% spike in operating expenses, resulting in net income falling short of Wall Street expectations for the third consecutive quarter, indicating pressure on profitability.
- Intellia Therapeutics Positive Development: Intellia Therapeutics' stock surged 12% after the FDA lifted the clinical hold on its investigational new drug application, although the shares remain below their October highs, reflecting a mix of market optimism and inherent risks regarding its future gene-editing therapies.
- Generate Biomedicines IPO Performance: Generate Biomedicines raised $400 million in its IPO but closed at $12.91 on its first trading day, down from its $16 offering price, indicating cautious market sentiment towards its AI-driven drug development approach, with Cathie Wood continuing to buy shares during this period.
- Market Competition and Investment Pressure: MercadoLibre faces competitive challenges in Brazil, compelling it to significantly lower minimum order requirements for free shipping; while its long-term investment strategy appears sound, the short-term decline in earnings expectations may adversely affect its stock performance.
See More
Wall Street Analysts Adjust GE Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on General Electric (GE) stock, indicating a shift in market sentiment, although specific rating changes were not detailed in the report.
- Market Reaction Insight: While specific upgrades or downgrades were not provided, the change in analysts' perspectives could influence investor decisions, particularly among those considering purchasing GE stock.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in market dynamics, and investors should pay attention to these changes to make informed investment choices.
- Overall Market Trends: Changes in analyst ratings often signal market expectations regarding a company's future performance, thus investors should closely monitor these updates to seize potential investment opportunities.
See More
Intellia Therapeutics FDA Lifts Clinical Hold on Nexizuran Trials
- Clinical Trial Progress: Intellia Therapeutics announced that the FDA has lifted the clinical hold on its phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), resulting in a 12% stock price increase on Monday, reflecting renewed market confidence in the drug.
- Historical Context: The clinical holds were imposed in October due to observed Grade 4 liver transaminase elevations and increased total bilirubin in a patient treated with nex-z, but both the MAGNITUDE and MAGNITUDE-2 trials have had their holds lifted, indicating progress in addressing safety concerns.
- Partnership Dynamics: The development of nex-z is in collaboration with Regeneron Pharmaceuticals, highlighting a joint effort to provide new treatment options for patients suffering from hereditary transthyretin amyloidosis with polyneuropathy, which could enhance patient outcomes.
- Financial Performance: Intellia reported a GAAP EPS of -$0.83 for Q4 2025, beating expectations by $0.12, while revenue reached $23.02M, exceeding forecasts by $10.85M, showcasing the company's potential in research and market expansion.
See More
Intellia Therapeutics Receives FDA Approval for Clinical Trial
- FDA Lifts Clinical Hold: The FDA has lifted the clinical hold on Intellia's MAGNITUDE trial, allowing the company to continue evaluating the efficacy and safety of nex-z in patients with transthyretin amyloidosis, which accelerates the advancement of its treatment options.
- Trial Enrollment Plans: Intellia aims to complete enrollment of approximately 1,200 patients in the MAGNITUDE trial and 60 patients in the MAGNITUDE-2 trial, ensuring data integrity and smooth trial progression, thereby laying the groundwork for future drug approval.
- Positive Stock Reaction: Intellia's shares rose 8.85% on Monday, reflecting a strong market reaction to the FDA's decision, with a 20% increase over the past 12 months indicating a favorable long-term trend for the company.
- Optimistic Analyst Ratings: The stock carries a Buy rating with an average price target of $19.73, with Chardan Capital and HC Wainwright & Co. maintaining and raising their targets, indicating strong market confidence in Intellia's future developments.
See More
Intellia Presents New Research at AAAAI Meeting
- Clinical Trial Results: In a pooled Phase 1/2 analysis involving 32 hereditary angioedema (HAE) patients, a single 50 mg dose of lonvo-z resulted in a mean monthly attack rate of ≤0.2, representing a 96% reduction from baseline, highlighting the potential long-term safety and efficacy of lonvo-z.
- Evolving Treatment Goals: Among 28 patients who received lonvo-z, 86% achieved attack-free and long-term prophylaxis-free status after more than six months of follow-up, indicating a strong alignment between patient needs for reduced treatment burden and clinical objectives.
- Biological Modeling Study: Research indicates that significant C1-esterase inhibitor deficiency in HAE patients leads to excessive plasma kallikrein generation, with models showing that an 85% reduction in prekallikrein can normalize kallikrein and bradykinin levels, supporting the clinical efficacy of lonvo-z.
- Patient Challenge Survey: A survey of 100 HAE patients revealed that 34% experienced at least one attack per month, with only 20% being attack-free in the past year, underscoring the demand for lonvo-z as patients seek to eliminate chronic medication use to improve treatment outcomes.
See More
INTELLIA THERAPEUTICS STOCK RISES 2% FOLLOWING US FDA'S LIFTING OF CLINICAL HOLD ON HEART DISEASE GENE THERAPY TRIAL
- Stock Performance: Intelia Therapeutics shares increased by 2% following a positive development in their clinical trial results.
- Clinical Trial Focus: The trial is centered on gene therapy for treating heart disease, specifically targeting a gene associated with the condition.
See More
Cathie Wood Continues to Add to Growth Stock Positions
- MercadoLibre Financial Analysis: MercadoLibre reported a 45% year-over-year increase in net revenue and financial income to $8.8 billion in Q4, yet its operating profit rose only 8% due to a 50% spike in operating expenses, resulting in net income falling short of Wall Street expectations for the third consecutive quarter, indicating pressure on profitability.
- Intellia Therapeutics Positive Development: Intellia Therapeutics' stock surged 12% after the FDA lifted the clinical hold on its investigational new drug application, although the shares remain below their October highs, reflecting a mix of market optimism and inherent risks regarding its future gene-editing therapies.
- Generate Biomedicines IPO Performance: Generate Biomedicines raised $400 million in its IPO but closed at $12.91 on its first trading day, down from its $16 offering price, indicating cautious market sentiment towards its AI-driven drug development approach, with Cathie Wood continuing to buy shares during this period.
- Market Competition and Investment Pressure: MercadoLibre faces competitive challenges in Brazil, compelling it to significantly lower minimum order requirements for free shipping; while its long-term investment strategy appears sound, the short-term decline in earnings expectations may adversely affect its stock performance.
See More
Wall Street Analysts Adjust GE Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on General Electric (GE) stock, indicating a shift in market sentiment, although specific rating changes were not detailed in the report.
- Market Reaction Insight: While specific upgrades or downgrades were not provided, the change in analysts' perspectives could influence investor decisions, particularly among those considering purchasing GE stock.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in market dynamics, and investors should pay attention to these changes to make informed investment choices.
- Overall Market Trends: Changes in analyst ratings often signal market expectations regarding a company's future performance, thus investors should closely monitor these updates to seize potential investment opportunities.
See More
Intellia Therapeutics FDA Lifts Clinical Hold on Nexizuran Trials
- Clinical Trial Progress: Intellia Therapeutics announced that the FDA has lifted the clinical hold on its phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), resulting in a 12% stock price increase on Monday, reflecting renewed market confidence in the drug.
- Historical Context: The clinical holds were imposed in October due to observed Grade 4 liver transaminase elevations and increased total bilirubin in a patient treated with nex-z, but both the MAGNITUDE and MAGNITUDE-2 trials have had their holds lifted, indicating progress in addressing safety concerns.
- Partnership Dynamics: The development of nex-z is in collaboration with Regeneron Pharmaceuticals, highlighting a joint effort to provide new treatment options for patients suffering from hereditary transthyretin amyloidosis with polyneuropathy, which could enhance patient outcomes.
- Financial Performance: Intellia reported a GAAP EPS of -$0.83 for Q4 2025, beating expectations by $0.12, while revenue reached $23.02M, exceeding forecasts by $10.85M, showcasing the company's potential in research and market expansion.
See More
Intellia Therapeutics Receives FDA Approval for Clinical Trial
- FDA Lifts Clinical Hold: The FDA has lifted the clinical hold on Intellia's MAGNITUDE trial, allowing the company to continue evaluating the efficacy and safety of nex-z in patients with transthyretin amyloidosis, which accelerates the advancement of its treatment options.
- Trial Enrollment Plans: Intellia aims to complete enrollment of approximately 1,200 patients in the MAGNITUDE trial and 60 patients in the MAGNITUDE-2 trial, ensuring data integrity and smooth trial progression, thereby laying the groundwork for future drug approval.
- Positive Stock Reaction: Intellia's shares rose 8.85% on Monday, reflecting a strong market reaction to the FDA's decision, with a 20% increase over the past 12 months indicating a favorable long-term trend for the company.
- Optimistic Analyst Ratings: The stock carries a Buy rating with an average price target of $19.73, with Chardan Capital and HC Wainwright & Co. maintaining and raising their targets, indicating strong market confidence in Intellia's future developments.
See More
